Efficacy, clinical and hemodynamic effects, safety andtolerability of sacubitril / valsartan in early initiation in patients with decompensated heart failureDownload in PDF
To evaluate the tolerability, efficacy and clinical outcomes of the initiation sacubitril/valsartan in the hospital inpatients stabilized after acute heart failure (AHF)
Material and methods
Thirty patients admitted to the cli-nic for an episode of AHF II-IV class NYHA and ejection fraction ≤40% (83.3% males, mean age of 66.0 [58.0-76.0]years) were included into the open-label study. Patients received the first dose of the study drug at least 6 hours prior to discharge from the hospital. The period of active treatment was 26 weeks. At week 12 and 26, we evaluated the number of patients who had achieved the target daily dose of 400 mg, and changes in signs and symptoms and severity of heart failure (HF) were evaluated. During the entire period of thestudy, safety parameters were investigated in all patients.
Sacubitril/valsartan is well tolerated, effective and safe drug in patients with chronic HF and a low ejection fraction.
Heart failure, sacubitril/valsartan, treatment.